Diabetic Retinopathy Market Growth Economies & The Companies That Propel Them Abbott Laboratories, Alimera Science, Allergan plc, Ampio Pharmaceuticals., Bayer, F. Hoffmann-La Roche, Novartis International AG, Pfizer & Others

Increase in prevalence of diabetes, rise in geriatric population, growth in incidence of blindness due to diabetes, and augment of focus on awareness that facilitates early diagnosis to control the diseases drive the market. However, this growth is limited by dearth of skilled ophthalmologists, and extended approval time for drugs. Conversely, emergence of combined therapies for treatment of diabetic macular edema and the emerging markets of the Asia-Pacific and LAMEA regions are expected to provide several opportunities for market growth during the forecast period.

Europe accounted for the highest market share in the industry in 2016, and is expected to maintain its dominance throughout the forecast period.

Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/2010

Diabetic Retinopathy Market was valued at $966 million in 2015, and is expected to reach $2,490 million by 2022, supported by a CAGR of 14.4% during the forecast period 2014 to 2022. Diabetic retinopathy (DR) is an eye disease associated with diabetic patients. The disease occurs when there is damage to the retina due to diabetes. Without timely treatment, the disease may lead to bleeding in the eyes, cloudy vision, and may even destroy the retina. DR is amongst the common cause of loss of vision in the diabetic population; eventually leading to blindness.

Diabetic retinopathy (DR) is a medical condition of the eye prevalent in diabetic individuals. It is mainly caused due to damage of the blood vessels of the retina. Without timely treatment, the disease leads to bleeding in the eyes, cloudy vision, and may even destroy the retina. DR is amongst the common cause of loss of vision in the diabetic population. From 1990 to 2010, DR holds the fifth position among the most common causes of preventable blindness and severe visual impairment.

The market is expected to witness significant growth during the forecast period due to factors such as increase in prevalence of diabetes, growth in geriatric population, rise in incidence of blindness due to diabetes, and augment in focus on awareness, which facilitates early diagnosis to control the diseases. Although these factors garner the growth of the market, dearth of skilled ophthalmologists and extended approval time for drugs can pose as a major obstacle for the growth of the diabetic retinopathy market. On the other hand, emergence of combined therapies for treatment of diabetic macular edema, and the emerging markets of the Asia-Pacific and LAMEA regions are anticipated to provide several opportunities for the market growth.

Proliferative diabetic retinopathy segment accounted for a major market share (more than half) in 2015 as the disease is one of the leading causes of blindness in diabetic patients. Moreover, nearly 20% of the people suffering from diabetic retinopathy (any type) have proliferative diabetic retinopathy.

North America accounted for majority of the share (nearly two-fifths) in the market in 2015, and is expected to remain dominant throughout the forecast period. This is attributed to the increase in incidence of diabetes along with the rise in geriatric population, increased patient awareness about diabetic retinopathy, and favorable reimbursement framework for retinopathy procedures. In addition, presence of highly sophisticated healthcare infrastructure is anticipated to provide new growth opportunities for the key players in this market.

The major companies profiled in the report include

- Abbott Laboratories,
- Alimera Science,
- Allergan plc,
- Ampio Pharmaceuticals.,
- Bayer AG,
- F. Hoffmann-La Roche,
- Novartis International AG,
- Pfizer,
- Regeneron Pharmaceuticals Inc., and
- Valeant Pharmaceutical.

Other key players in the value chain include Boehringer Ingelheim GmbH, KOWA Company, Ltd., BCN Peptides S.A., and ThromboGenics NV.

Get Customized Report as Required @ https://www.alliedmarketresearch.com/request-for-customization/2010

LIST OF TABLES

TABLE 1. GLOBAL DIABETIC RETINOPATHY MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 2. GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY MARKET, BY TREATMENT TYPE, 2014-2022 ($MILLION)
TABLE 3. GLOBAL DIABETIC MACULAR EDEMA (DME) MARKET, BY TREATMENT TYPE, 2014-2022 ($MILLION)
TABLE 4. GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY MARKET, BY REGION, 2014-2022 ($MILLION)
TABLE 5. GLOBAL DIABETIC MACULAR EDEMA (DME) MARKET, BY REGION, 2014-2022 ($MILLION)
TABLE 6. GLOBAL DIABETIC RETINOPATHY MARKET, BY TREATMENT TYPE, 2014-2022 ($MILLION)
TABLE 7. GLOBAL ANTI VEGF MARKET FOR DIABETIC RETINOPATHY, BY REGION, 2014-2022 ($MILLION)
TABLE 8. GLOBAL STEROID IMPLANTS MARKET FOR DIABETIC RETINOPATHY, BY REGION, 2014-2022 ($MILLION)
TABLE 9. GLOBAL LASER SURGERIES MARKET FOR DIABETIC RETINOPATHY, BY REGION, 2014-2022 ($MILLION)
TABLE 10. GLOBAL VITRECTOMY MARKET FOR DIABETIC RETINOPATHY, BY REGION, 2014-2022 ($MILLION)
TABLE 11. GLOBAL DIABETIC RETINOPATHY MARKET, BY REGION, 2014-2022 ($MILLION)
TABLE 12. NORTH AMERICA DIABETIC RETINOPATHY MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 13. NORTH AMERICA DIABETIC RETINOPATHY MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 14. NORTH AMERICA DIABETIC RETINOPATHY MARKET, BY TREATMENT TYPE, 2014-2022 ($MILLION)
TABLE 15. EUROPE DIABETIC RETINOPATHY MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 16. EUROPE DIABETIC RETINOPATHY MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 17. EUROPE DIABETIC RETINOPATHY MARKET, BY TREATMENT TYPE, 2014-2022 ($MILLION)
TABLE 18. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 19. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 20. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET, BY TREATMENT TYPE, 2014-2022 ($MILLION)
TABLE 21. LAMEA DIABETIC RETINOPATHY MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 22. LAMEA DIABETIC RETINOPATHY MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 23. LAMEA DIABETIC RETINOPATHY MARKET, BY TREATMENT TYPE, 2014-2022 ($MILLION)
TABLE 24. ABBOTT: COMPANY SNAPSHOT
TABLE 25. ALIMERA: COMPANY SNAPSHOT
TABLE 26. ALLERGAN: COMPANY SNAPSHOT
TABLE 27. AMPIO: COMPANY SNAPSHOT
TABLE 28. BAYER: COMPANY SNAPSHOT
TABLE 29. ROCHE: COMPANY SNAPSHOT
TABLE 30. NOVARTIS: COMPANY SNAPSHOT
TABLE 31. PFIZER: COMPANY SNAPSHOT
TABLE 32. REGENERON PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 33. VALEANT PHARMACEUTICAL: COMPANY SNAPSHOT

Access Full Summery @ https://www.alliedmarketresearch.com/press-release/diabetic-retinopathy-market.html

About Us

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

Contact

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

This release was published on openPR.